Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 9/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649459 | 1.00 | METAP2 (0.43) | METAP2PTGES2ALDH1A1KRASATM | |
| SCHEMBL6844921 | 1.00 | METAP2 (0.43) | METAP2PTGES2ALDH1A1KRASATM | |
| SCHEMBL1649449 | 0.92 | METAP2 (0.42) | METAP2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL14717298 | 0.91 | METAP2 (0.48) | METAP2PTGES2ALDH1A1KRASATM | |
| SCHEMBL14717297 | 0.91 | METAP2 (0.48) | METAP2PTGES2ALDH1A1KRASATM | |
| SCHEMBL436523 | 0.89 | METAP2 (0.57) | METAP2PTGES2KCNH2 | |
| SCHEMBL462418 | 0.89 | METAP2 (0.42) | METAP2PTGES2POLB | |
| SCHEMBL462796 | 0.89 | METAP2 (0.57) | METAP2PTGES2KCNH2 | |
| SCHEMBL462417 | 0.89 | METAP2 (0.42) | METAP2PTGES2POLB | |
| SCHEMBL14717510 | 0.89 | METAP2 (0.57) | METAP2PTGES2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | METAP2 1/4885PTGES2 524/4885ALDH1A1 360/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | METAP2 1/4885PTGES2 524/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.